Evidence map›Paper›PMID 40960635›Full record

ReviewZeitschrift fur Rheumatologie2025

[VEXAS syndrome].

M Krusche, N Ruffer, I Kötter, K Sockel

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M KruscheSektion für Rheumatologie und Entzündliche Systemerkrankungen in der III. Medizin, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland. m.krusche@uke.de.
N RufferSektion für Rheumatologie und Entzündliche Systemerkrankungen in der III. Medizin, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland.
I KötterSektion für Rheumatologie und Entzündliche Systemerkrankungen in der III. Medizin, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland.
K SockelMedizinische Klinik und Poliklinik I, Universitätsklinikum Carl-Gustav Carus Dresden, TU Dresden, Dresden, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The VEXAS (vacuoles, E1 enzyme, X‑linked, autoinflammatory, somatic) syndrome is an acquired autoinflammatory disease, which is based on somatic mutations in the UBA1 gene and described as an hematoinflammatory disease. It is clinically expressed as an inflammatory systemic disease with general vegetative symptoms and organ manifestations of the skin, lungs and the hematopoietic system. The symptoms are not uncommonly refractory to conventional anti-inflammatory therapeutic agents. The disease is associated with a clearly increased mortality and morbidity.

Indexed as

Hereditary Autoinflammatory DiseasesUbiquitin-Activating EnzymesAnti-Inflammatory AgentsDiagnosis, DifferentialGenetic Predisposition to DiseaseHumansMyelodysplastic SyndromesSkin Diseases, GeneticSyndromeAnti-Inflammatory AgentsUBA1 protein, humanUbiquitin-Activating EnzymesAutoinflammatory diseaseGeneral vegetative symptomsHematoinflammatory diseaseInflammatory systemic diseaseOrgan manifestations

Identifiers

PMID40960635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.